Cart
sales@molnova.com
NQDI-1
CAS No. 175026-96-7
NQDI-1( NQDI 1 )
Catalog No. M12650 CAS No. 175026-96-7
NQDI-1 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with Ki of 500 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 42 | In Stock |
|
| 10MG | 72 | In Stock |
|
| 25MG | 150 | In Stock |
|
| 50MG | 295 | In Stock |
|
| 100MG | 444 | In Stock |
|
| 500MG | 1008 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNQDI-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionNQDI-1 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with Ki of 500 nM.
-
DescriptionNQDI-1 is a potent and selective inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with Ki of 500 nM; inhibits in vivo expression levels of ASK1, phosphorylated (p?)JNK, p?c?Jun, p53 and caspase 3 in Hypoxia-ischemia rat model; enhances endochondral bone formation by increasing chondrocyte survival in mice.
-
In VitroThe selectivity of NQDI-1 is evaluated in vitro on four serine/threonine protein kinases (protein kinase CK2 (CK2), c-Jun N-terminal kinase 3 (JNK3), Rho-associated protein kinase 1 (Rock1), and Aurora A) and three tyrosine protein kinases (FGFR1, hHGFR, and endothelial TEK tyrosine kinase (Tie2)). The results show that NQDI-1 is a selective inhibitor of ASK1. The activity of FGFR1 protein kinase is inhibited by NQDI-1 (residual activity of 44%). NQDI-1 inhibits ASK1 with a Ki of 500 nM. Inhibition of ASK1 by NQDI-1 is competitive with respect to the phosphodonor substrate ATP.
-
In Vivo250 nmol NQDI-1 in DMSO is intracerebroventricularly injected following brain insult. Western blotting is performed to determine the expression of ASK1 in the sham, Hypoxia-ischemia (HI), DMSO and NQDI-1 groups and indicate that NQDI-1 markedly inhibits the expression of ASK1 in the brain cortex, compared with the HI and DMSO group. Furthermore, immunofluorescence staining also indicates that the expression of ASK1 is inhibited by NQDI-1 in the brain cortex. The expression of downstream targets of ASK1 is also determined in the present study. The expression levels of p-JNK, p-c-Jun, p53 and caspase 3 are significantly decreased by NQDI-1, compared with the HI and DMSO groups. Low expression of p-JNK in the brain cortex is also observed by immunofluorescence in the NQDI-1-treated group.
-
SynonymsNQDI 1
-
PathwayMAPK/ERK Signaling
-
TargetMEK
-
RecptorASK1|MAP3K5
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number175026-96-7
-
Formula Weight319.3108
-
Molecular FormulaC19H13NO4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mg/mL
-
SMILESO=C(C1=C2C3=C(NC1=O)C=CC=C3C(C4=C2C=CC=C4)=O)OCC
-
Chemical Name3H-Naphtho[1,2,3-de]quinoline-1-carboxylic acid, 2,7-dihydro-2,7-dioxo-, ethyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Volynets GP, et al. J Med Chem. 2011 Apr 28;54(8):2680-6.
2. Hao H, et al. Mol Med Rep. 2016 Jun;13(6):4585-92.
3. Eaton GJ, et al. Cell Death Dis. 2014 Nov 13;5:e1522.
molnova catalog
related products
-
G 573
G 573 is a potent and selective, allosteric inhibitor of MEK with Ki of 0.3 nM; blocks MEK phosphorylation by BRAF(V600E).
-
MEKK2 inhibitor 1s
MEKK2 inhibitor 1s (MEKK2-IN-1s) is a potent MEKK2 (MAP3K2) inhibitor with IC50 of 16 nM, inhibits MEKK2 and MEKK3 with similar potencies.
-
Etacrynic acid
A loop diuretic used to treat high blood pressure and the swelling, a novel ligand and inhibitor of MAP2K6 kinase that inhibits MAP2K6 in part through alkylation of a nonconserved cysteine residue.
